Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Feb 2010

Dacic Sanja, Shuai Yongli, Yousem Samuel, Ohori Paul, Nikiforova Marina

Abstract excerpt

Screening for EGFR and KRAS mutations in patients with lung adenocarcinomas can be used to predict the patient's response to EGFR tyrosine kinase inhibitors, but there is a lack of guidelines for testing in clinical practice. We analyzed the morphological and clinicopathological characteristics,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Cost-Benefit Analysis
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Situ Hybridization, Fluorescence

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 19855375
DOI: 10.1038/modpathol.2009.154

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19855375-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.PMID 19855375Read ↗

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.Semantic proximity Read ↗

EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.Semantic proximity Read ↗

Correlation of Histologic Subtypes and Molecular Alterations in Pulmonary Adenocarcinoma: Therapeutic and Prognostic Implications.Semantic proximity Read ↗

Simplified Molecular Classification of Lung Adenocarcinomas Based on EGFR, KRAS, and TP53 MutationsSemantic proximity Read ↗

KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.Semantic proximity Read ↗

EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.Semantic proximity Read ↗

Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.Semantic proximity Read ↗

Clinicopathological Features and Prognosis of Lung Adenocarcinoma Patients With K-RAS Gene Mutation.Semantic proximity Read ↗

Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?Semantic proximity Read ↗

Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.Semantic proximity Read ↗

Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.Semantic proximity Read ↗

Development and validation of a multivariable predictive model for EGFR gene mutation status in patients with lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.